PolarityTE Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE to Support Chronic Cutaneous Ulcer Indication
SALT LAKE CITY, Jan. 18, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced that…
